返回 Agenda
Is the Future Bright for Treatment of Neurodegenerative Diseases?
Session Chair(s)
Susan Yule
Senior Global Regulatory Leader
F. Hoffmann-La Roche Ltd., Switzerland
Despite decades of research, we continue to search for meaningful treatment in neurodegenerative diseases such as Alzheimer's and Parkinson's. This session will focus on the impact of patient associations on the progress of treatment. A case study will be explored.
Learning Objective : Discuss where we are today and what is the future in treatment of diseases such as Alzheimer's or Parkinson's; Describe the impact the associations have had in improving treatment.
Speaker(s)
Recent Approaches and the Future of Neurodegenerative Diseases
Conrad Hawkins
KMR Group Inc., United States
Associate Consultant
Challenges in Drug Development of Disease Modifying Drugs in Alzheimer's Disease
Laura Gault, MD, PHD
AbbVie, Inc., United States
Group Project Leader
How Patients Can Help Regulators to Bring New Treatments for Neurodegenerative Diseases?
Juan Garcia-Burgos, MD, PHD
European Medicines Agency, Netherlands
Head of Public and Stakeholders Engagement Department
Industry Perspective
Jamie A. Mullen, MD
AstraZeneca, United States
Global Clinical Leader